Bowery Clinic Review

What Bowery Clinic charges

• BPC-157: $149/mo — one-time price for a single 800 mcg unit the page says "Lasts approximately 4 weeks"; the same page states "There are no additional subscription or shipping fees - what you see is exactly what you pay"
• KPV: $149/mo — one-time price for a 600 mcg troche the page says "Lasts approximately 4 weeks"
• CJC-1295: $299/mo — sold only paired with ipamorelin; one-time price for the 30 mg vial or 1400 mcg troche the page says "Lasts approximately 4 weeks"
• Ipamorelin: $299/mo — sold only paired with CJC-1295; one-time price for the 30 mg vial or 1400 mcg troche the page says "Lasts approximately 4 weeks"
• MOTS-C: $249/mo — one-time price for a 10 mg vial the page says "Lasts approximately 5 weeks", so it is not a calendar-month figure
• Epitalon: $249/mo — one-time price for a 10 mg vial the page says "Lasts approximately 5 weeks"; the catalog spells it Epithalon
• Semax: $199/mo — one-time price for a 45 mg nasal spray the page says "Lasts approximately 5 weeks", so it is not a calendar-month figure
• Sermorelin: $199/mo — flat product-page price; the strength and the supply length printed beside it were not recorded in this pass, so this figure carries no term
• NAD+: $199/mo — flat product-page price; the strength and the supply length printed beside it were not recorded in this pass, so this figure carries no term
• GHK-Cu: $249/mo — flat product-page price; the strength and the supply length printed beside it were not recorded in this pass, so this figure carries no term
• Tesamorelin: $249/mo — flat product-page price; the strength and the supply length printed beside it were not recorded in this pass, so this figure carries no term

A price with a quantity attached to it

Each product page prints three things at once: a figure, the strength that figure buys, and a sentence saying roughly how long the unit lasts. Most of the catalog is described as lasting approximately four weeks.

Three of the recorded figures are not four-week ones. Semax, MOTS-c and Epithalon are each described as lasting approximately five weeks, so those figures buy longer than a month and should not be read as monthly costs.

Several peptides are offered as a dissolvable troche as well as a vial, which makes a good part of the menu usable without injecting at all. The troche and the vial are quoted at the same figure where both formats exist.

The Terms undo what the product pages promise

The product pages state that there are no additional subscription or shipping fees and that what you see is exactly what you pay. The Terms of Service say charges may include consultation fees, laboratory or diagnostic services, and membership or administrative fees.

Both statements are published by the same seller, on the same site, today. Neither one is buried; they simply do not agree, and the one a shopper is most likely to read is the one on the product page.

Section 32 of those same Terms goes further, describing the products as not intended for human or animal consumption of any kind and as not medical treatments. That is standard research-vial boilerplate, and it sits oddly on a site that sells prescribed therapy through a clinical entity.

The operator is named in the Terms rather than left to inference: Salk Health USA Inc., doing business as Bowery Clinic, alongside Hoedebecke Clinic P.C., described as an independent professional corporation providing the clinical services.

What is on the menu, and what this site will not record

Sermorelin, NAD+, GHK-Cu and tesamorelin each have their own page here, on top of BPC-157, KPV, CJC-1295 with ipamorelin, MOTS-c, Epithalon and Semax. That is eleven of the sixteen compounds this site tracks, from one seller, and tirzepatide makes twelve.

Four of those eleven were captured without the strength printed alongside the figure. Their rows say so rather than borrowing a strength from a neighbouring product, which is why they read differently from the rest.

The catalog also carries Selank, DSIP, Dihexa, AOD-9604, Enclomiphene and Methylene Blue. None of those is in this site's sixteen-compound registry, so none of them is scored or compared here.

One entry is deliberately left unmapped. The site sells a product it spells TB-400, and this site does not record that as TB-500: the registry has no entry for the seller's spelling, and mapping one peptide onto a similarly named one is exactly the guess the registry exists to prevent.

Tirzepatide is sold and priced, and it still carries no price row here. The page labels the vial as lasting approximately three months, so storing that figure in a field called monthly would overstate the cost threefold, and this site does not divide a published figure out to make it fit.

Nothing published about states, and no pharmacy named

There is no state list anywhere. The Terms say only that clinical services are provided in states where the providers are licensed and that availability may change without notice, which tells a shopper nothing they can check before signing up.

Ten of the twenty-three sellers compared on this site publish a state list of some kind. This is one of the thirteen that do not.

The pharmacies are described as 503A FDA-registered and never named. Six of the twenty-three sellers here name the facility that fills an order; naming one is what makes it possible to look the facility up.

None of the peptides on this menu is an FDA-approved finished drug. A 503A pharmacy compounds to a prescription, and the description of that pharmacy as FDA-registered is a fact about the facility, not about any product it makes.

How we verified this

• Read each peptide product page and recorded the figure, the format, the strength where one was printed, and the stated supply length verbatim.
• Recorded the four ranked-board figures whose product pages were captured without a strength beside them, and marked those rows as incomplete rather than filling the gap.
• Read the Terms of Service in full and recorded both the fee clause and the Section 32 consumption wording as published.
• Confirmed the operating entity from those same Terms rather than from the brand name on the homepage.
• Checked the site for a state list, found none, and recorded the Terms' licensing sentence in its place.
• Left the TB-400 product unmapped after confirming this site's compound registry has no entry for that spelling.